The stock of eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) last traded at $0.54, down -2.01% from the previous session.
Data from the available sources indicates that eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) is covered by 5 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $3.00, we find $10.00. Given the previous closing price of $0.55, this indicates a potential upside of 1718.18 percent. EFTR stock price is now -7.03% away from the 50-day moving average and -73.90% away from the 200-day moving average. The market capitalization of the company currently stands at $20.30M.
In total, 1 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $10.20 as their price target over the next twelve months.
With the price target reduced from $20 to $6.20, Stifel Downgraded its rating from Buy to Hold for eFFECTOR Therapeutics Inc. (NASDAQ: EFTR). On November 09, 2021, Stifel Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $20, while ‘Credit Suisse’ rates the stock as ‘Outperform’.
In other news, Ehrlich Christopher B, Director bought 346 shares of the company’s stock on Oct 04. The stock was bought for $197 at an average price of $0.57. Upon completion of the transaction, the Director now directly owns 35,213 shares in the company, valued at $19015.02. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 26, Director Ehrlich Christopher B bought 18,867 shares of the business’s stock. A total of $10,377 was incurred on buying the stock at an average price of $0.55. This leaves the insider owning 34,867 shares of the company worth $18828.18. Insiders disposed of 809,773 shares of company stock worth roughly $0.44 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EFTR stock. A new stake in eFFECTOR Therapeutics Inc. shares was purchased by WESCOTT FINANCIAL ADVISORY GROUP, LLC during the first quarter worth $30,000. TWO SIGMA INVESTMENTS, LP invested $26,000 in shares of EFTR during the first quarter. In the first quarter, MGO ONE SEVEN LLC acquired a new stake in eFFECTOR Therapeutics Inc. valued at approximately $11,000. UBS GROUP AG acquired a new stake in EFTR for approximately $9,000. TWO SIGMA SECURITIES, LLC purchased a new stake in EFTR valued at around $9,000 in the second quarter.
During the past 12 months, eFFECTOR Therapeutics Inc. has had a low of $0.46 and a high of $9.67. As of last week, the company has a debt-to-equity ratio of 0.96, a current ratio of 1.80, and a quick ratio of 1.80.
The company reported revenue of $0.87 million for the quarter, compared to $0.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 103.04 percent.
eFFECTOR Therapeutics Inc.(EFTR) Company Profile
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.